Advertisement

Topics

Latest "Puretech" News Stories

20:54 EST 14th December 2018 | BioPortfolio

Here are the most relevant search results for "Puretech" found in our extensive news archives from over 250 global news sources.

More Information about Puretech on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Puretech for you to read. Along with our medical data and news we also list Puretech Clinical Trials, which are updated daily. BioPortfolio also has a large database of Puretech Companies for you to search.

Showing "Puretech" News Articles 1–25 of 62

Tuesday 11th December 2018

BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers

In this connection, the Bristol-Myers Squibb and Vedanta Biosciences, an affiliate of PureTech Health, have entered into a clinical collaboration. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, The post BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers appeared first on Pharmaceutical Business review.


Monday 10th December 2018

Bristol-Myers and Vedanta to study combination therapy for cancer

Bristol-Myers Squibb has partnered with PureTech Health subsidiary Vedanta Biosciences to study its Opdivo in combination with VE800 drug candidate...Read More... The post Bristol-Myers and Vedanta to study combination therapy for cancer appeared first on Pharmaceutical Technology.

Karuna Pharmaceuticals to Present Results of KarXT Phase 1 Study at American College of Neuropsychopharmacology Annual Meeting

CMO Stephen Brannan to present Phase 1 results of a multi-dose safety study aimed at optimizing combination of Xanomeline and Trospium Chloride Proprietary co-formulation being evaluated in ongoing Phase 2 with results expected in 2019 Karuna Pharmaceuticals, Inc. (“Karuna”), focused on targeting muscarinic cholinergic receptor...


Wednesday 5th December 2018

resTORbio Inc TORC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryresTORbio Inc resTORbio a subsidiary of Puretech Health plc is a clinicalstage biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of agingrelated diseases. Its pipeline product candidate RTB101, an orally administered, small molecule, potent TORC1 inhibitor alone or in combination with everolimus used for the treatment of respirat...

Thursday 29th November 2018

Vor Biopharma secures US patent covering compositions and methods to treat haematologic malignancies

Vor Biopharma is an immuno-oncology company pioneering haematopoietic stem cell (HSC) therapies for the treatment of haematological malignancies and affiliate of PureTech Health. This foundational patent is the The post Vor Biopharma secures US patent covering compositions and methods to treat haematologic malignancies appeared first on Pharmaceutical Business review.

PureTech’s Vor secures US patent for compositions and methods to treat hematologic malignancies

This foundational patent is the first of its kind in the immuno-oncology field and it broadly covers compositions and therapeutic methods related to using novel modified HSCs to The post PureTech’s Vor secures US patent for compositions and methods to treat hematologic malignancies appeared first on Pharmaceutical Business review.

Wednesday 28th November 2018

Vor Biopharma Announces Issuance of Foundational U.S. Patent Broadly Covering Compositions and Methods to Treat Hematologic Malignancies

The patent covers first-in-class novel hematopoietic stem cell technology for targeted immunotherapies in hematologic malignancies Vor Biopharma, an immuno-oncology company pioneering hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies and affiliate of PureTech Health plc (LSE: PRTC), today ann

Tuesday 27th November 2018

Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease

First clinical study of a rationally-defined bacterial consortium for an immune-mediated disease Milestone triggers $12 million in payments from Janssen Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacte...

Thursday 15th November 2018

Puretech Health plc PRTC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryPuretech Health plc Puretech, formerly PureTech Ventures LLC is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company offers human proof of concept and pivotal stage programs. It develops a microbiome immune system drugdiscovery platform and drug candidates for immunemediated diseases; and pr...

Tuesday 13th November 2018

Akili Builds Medical Team with Newly Appointed Medical Affairs Leader and Formation of Clinical Advisory Committee in Preparation for Commercial Launch

Anil S. Jina, M.D., Joins Akili to Build and Lead Medical Affairs Team Leading Clinicians and Researchers Will Advise on the Expansion of Akili’s Lead Investigational Product and Pipeline of Digital Medicine Products Akili Interactive (“Akili” or “Company"), a leading prescription digital medicine company developing no...

Pivotal Weight Loss Data for Gelesis100 Published in Obesity, Including Predictors of Response

6 out of 10 of adults with overweight or obesity had a clinically meaningful response to Gelesis100, losing on average 10% of their weight (22 pounds) and nearly 4 inches from their waists. Adults treated with Gelesis100 had twice the odds of achieving ≥ 5% and ≥ 10% total body weight loss compared to placebo Successful response to Gelesis100 ...

Wednesday 7th November 2018

PureTech Health to Present at Jefferies 2018 London Healthcare Conference

PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis, today announced that Joep Muijrers, Ph.D., Chief Financial Officer at PureTech Health, will present at the Jefferies 2018 Global Healthcare Conference in London on Thursday, November ...

Tuesday 6th November 2018

Vedanta Biosciences Announces Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate

VE800 shown to induce cytotoxic T cells and a systemic immune response both as a monotherapy and in combination with checkpoint inhibitors First detailed description of anti-tumor activity mediated by commensal bacteria that have been associated with clinical response to checkpoint inhibitors These data to be presented at the Socie...

Monday 5th November 2018

Gelesis Announces Presentations of Expanded Pivotal Data at ObesityWeek 2018

Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, today announced that the Company will deliver an oral presentation and three poster presentations at ObesityWeek 2018, the annual combined congress of the American Society for Metabolic ...

Monday 22nd October 2018

resTORbio Inc TORC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12092018] Prices from USD $250

SummaryresTORbio Inc resTORbio a subsidiary of Puretech Health plc is a clinicalstage biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of agingrelated diseases. Its pipeline product candidate RTB101, an orally administered, small molecule, potent TORC1 inhibitor alone or in combination with everolimus used for the treatment of respirat...

Wednesday 17th October 2018

Karuna Appoints Jeff Jonas, M.D., to Board of Directors

Industry leader brings extensive experience in building and leading clinical development programs for central nervous system disorders Karuna Pharmaceuticals, Inc. (“Karuna”), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by psychosis and cognitive impairment, today announced the ...

Tuesday 16th October 2018

PureTech affiliate Karuna advances schizophrenia candidate

Karuna Pharmaceuticals, an affiliate of UK biopharma PureTech Health, has kicked off a Phase II study of KarXT, which is being developed for the treatment of psychosis in schizophrenia.

Monday 15th October 2018

Karuna Announces First Patient Dosed in Phase 2 Study of Lead Product Candidate KarXT for the Treatment of Schizophrenia

Phase 2 study aims to reproduce significant efficacy previously observed in schizophrenia trial with xanomeline alone Company also announces successful Phase 1 study of proprietary xanomeline and trospium chloride co-formulation, which will be used in Phase 2 study Karuna Pharmaceuticals, Inc. (“Karuna”), focused on target...

Thursday 4th October 2018

Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303

All doses were safe and well-tolerated VE303 treatment resulted in rapid, durable, dose-dependent colonization and accelerated gut microbiota restoration after antibiotics A Phase 2 study in recurrent C. difficile infection is expected to begin in the fourth quarter of 2018 Three other programs in immuno-oncology, allergy, and in...

Monday 17th September 2018

PureTech Health Collaborator Publishes in Nature Neuroscience Highlighting Key Role of Brain Lymphatics in Neuroinflammatory Conditions Like Multiple Sclerosis

Work identifies junction between brain and lymphatics system, offering new insights into disease pathology Novel therapeutic approach to target neuroinflammation enabled by a deeper understanding of pathogenic immune cell trafficking between the CNS and the brain lymphatics Underlying intellectual property is exclusively licensed by PureT...

Thursday 13th September 2018

Puretech Health plc PRTC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09052018] Prices from USD $250

SummaryPuretech Health plc Puretech, formerly PureTech Ventures LLC is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company offers human proof of concept and pivotal stage programs. It develops a microbiome immune system drugdiscovery platform and drug candidates for immunemediated diseases; and pr...

Wednesday 12th September 2018

Akili Announces Exclusive Licensing Agreement for New Digital Technology Integrating Neural Systems Targeting and Physical Activity as Novel Cognitive Dysfunction Treatment Platform

Developed by leading neuroscientists at the U.C. San Francisco, currently in multiple clinical trials Technology is latest in series of new potential digital treatments Akili is pursuing Akili Interactive (“Akili” or “Company"), a leading prescription digital medicine company developing novel treatments

U.S. Department of Defense Awards $3.3 Million Grant to Alivio Therapeutics

Research award will support preclinical activities to advance product candidate for the treatment of interstitial cystitis/bladder pain syndrome into the clinic Alivio Therapeutics, an affiliate of

Monday 10th September 2018

Karuna closes $42mm Series A round to advance KarXT schizophrenia candidate

CNS-focused Karuna Pharmaceuticals Inc. (muscarinic receptors for psychiatric and cognitive disorders) raised $42mm in a Seri...

Wednesday 5th September 2018

PureTech’s Vedanta Biosciences adds Susan Dillon to Board of Directors


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks